Impacto de la reducción de dosis de estavudina en su perfil de eficacia/seguridad en pacientes con infección por el virus de la inmunodeficiencia humana inmunológica y virológicamente estables

Pedrol, Enric; Martín, Teodoro; Pozo, Miguel Ángel del; Flores, Juan; Sanz, José; Cartón, José A; Jusdado, Juan-José; Arazoh, Piedad; Ribera, Esteve; Deiga, Elisabet.
Med. clín (Ed. impr.) ; 129(10): 361-365, sept. 2007. tab, graf
Artículo en Es | IBECS (España) | ID: ibc-63462

Documentos relacionados

  1. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
  2. Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis.
  3. New oral agents for treating dyslipidemia.
  4. Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials.
  5. Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease.
  6. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
  7. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
  8. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
  9. The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis.
  10. Bempedoic Acid: A New Drug for an Old Problem.